Biotech https://www.benzinga.com/views/taxonomy/term/19868 en Arrayit Corporation Announces Nationwide Allergy Testing Sales and Distribution Network https://www.benzinga.com/pressreleases/18/06/g11891938/arrayit-corporation-announces-nationwide-allergy-testing-sales-and-dis <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p>Sunnyvale, June 18, 2018 (GLOBE NEWSWIRE) -- <b>Arrayit Corporation Announces Nationwide Allergy Testing Sales and Distribution Network</b></p> <p>June 18, 2018 - Sunnyvale, CA – Arrayit Corporation (OTC: <a href="https://www.globenewswire.com/Tracker?data=3TK4obYbMod5TTz2k-MgVVY1S0Mwor7Hdqp12Jl_ev19vGPEi9nua4_pMp-TaErCs8Gj0wfxtLqhKzueo-4AWg==" rel="nofollow" target="_blank" rel="nofollow"><u>ARYC</u></a>), a life sciences and personalized medicine company, announces that the company has engaged a nationwide network of professional sales representatives ("sales reps") to sell and distribute the company&#039;s allergy tests across the Continental United States, with focus areas in the Pacific Northwest, West, Southwest, Rocky Mountain, Midwest, Northeast and Southeast regions.  The network comprises 1,700 sales professionals including 500 sales reps with specific training in finger stick sampling, blood card collection and microarray technology.  This extensive professional network will be used to enroll hospitals, health maintenance organizations (HMOs), doctor&#039;s and dentist&#039;s offices, health clinics and retail stores into the allergy-testing program.</p> <p>Arrayit allergy tests utilize non-invasive and convenient finger stick sampling and blood ...</p><p><a href=https://www.benzinga.com/pressreleases/18/06/g11891938/arrayit-corporation-announces-nationwide-allergy-testing-sales-and-dis alt=Arrayit Corporation Announces Nationwide Allergy Testing Sales and Distribution Network>Full story available on Benzinga.com</a></p> ARYC Biotech Health Care Press Releases General ARYC Biotech Health Care Press Releases General Benzinga Mon, 18 Jun 2018 09:30:00 +0000 Globe Newswire 11891938 at https://www.benzinga.com The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs https://www.benzinga.com/general/biotech/18/06/11880427/the-week-ahead-in-biotech-conferences-clinical-trials-and-ipos <p>Sentiment toward biotech stocks turned neutral this week amid a lack of any major sectorwide catalysts. That said, there were wild swings in select stocks in reaction to clinical trial announcements.&nbsp;</p> <p>Here are a few catalytic events in the upcoming week that should be on the radar of every biotech investor.</p> <h3>Medical, Health Care And Biotech Conferences</h3> <ul> <li>23rd Congress of European Hematology Association: June 14-17&nbsp;in Stockholm, Sweden.</li> <li>52nd European Human Genetics Conference in conjunction with the European Meeting on Psychological Aspects of Genetics: June 16-19&nbsp;in Milan, Italy.</li> <li>JMP Securities Annual Life Sciences Conference: June 20-21 in New York.</li> <li>World Congress On Gastrointestinal Cancer: June 20-23 in Barcelona, Spain.</li> <li>American Diabetes Association&#39;s 78th Scientific Sessions: June 22-26&nbsp;in Orlando, Florida.&nbsp;</li> </ul> <p><em>See Also: <a href="https://www.benzinga.com/general/biotech/18/06/11796974/attention-biotech-investors-mark-your-calendar-for-these-june-pdufa-d">Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates</a></em></p> <h3>PDUFA Dates</h3> <p>The FDA is set to rule on <strong> Valeant Pharmaceuticals Intl Inc </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vrx#NYSE">VRX</a>)&#39;s <a href="http://ir.valeant.com/news-releases/2017/11-02-2017-110334423">NDA</a> for IDP-118, a topical lotion being evaluated for plaque psoriasis in adult patients, on Monday, June 18.</p> <h3>Clinical Trial Presentations</h3> <p><strong>Sarepta Therapeutics Inc </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/srpt#NASDAQ">SRPT</a>) is due to release Phase 1/2 data on its microdystrophin gene therapy for Duchenne muscular dystrophy on Tuesday, June 19. The <a href="https://www.benzinga.com/analyst-ratings/analyst-color/18/03/11397171/turning-neutral-morgan-stanley-downgrades-sarepta-loxo-">stock</a> has nearly doubled year-to-date.</p> <p><strong>Array Biopharma Inc ...</strong></p><p><a href=https://www.benzinga.com/general/biotech/18/06/11880427/the-week-ahead-in-biotech-conferences-clinical-trials-and-ipos alt=The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs>Full story available on Benzinga.com</a></p> APTX ARRY AUTL AVRO Biotech ECOR IBB ITRM KNSA KZR MGTA News SRPT VRX XERS ZFGN Previews IPOs Trading Ideas General ARRY US04269X1054 IBB US4642875565 VRX CA91911K1021 SRPT ZFGN ITRM AUTL KNSA ECOR APTX MGTA XERS KZR AVRO News Biotech Previews IPOs Trading Ideas General Benzinga Sun, 17 Jun 2018 20:16:03 +0000 Shanthi Rexaline 11880427 at https://www.benzinga.com Intellia Confirms Crispr Risk Irrelevant To Its Program, With No Adjustments Needed https://www.benzinga.com/general/biotech/18/06/11888006/intellia-confirms-crispr-risk-irrelevant-to-its-program-with-no-adjus <p>On Monday, <strong>Crispr Therapeutics AG</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crsp#NASDAQ">CRSP</a>) <a href="http://www.benzinga.com/general/biotech/18/06/11860182/crispr-therapeutics-falls-as-studies-suggest-p">dragged down its community of clients</a>, including <strong>Intellia Therapeutics Inc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntla#NASDAQ">NTLA</a>), after two scientific <a href="https://www.statnews.com/2018/06/11/crispr-hurdle-edited-cells-might-cause-cancer/">reports</a> warned of a possible link between CRISPR-Cas9 applications and cancer.</p> <p>Thomas&nbsp;Barnes, senior vice president of Intellia&rsquo;s innovative sciences, said the investor alarm was unwarranted.</p> <p>As Barnes sees it, the findings have been &ldquo;sensationalized.&rdquo;</p> <h3><strong>Intellia: Reports Show Nothing New</strong></h3> <p>Key nuances in the studies were overlooked, Barnes said.&nbsp;</p> <p>&ldquo;What these papers said, and this has been completely lost in the reporting, was some cells are very sensitive to double-strand breaks,&rdquo; Barnes told Benzinga. &ldquo;Not all cells, some cells. When you are sensitive to a double-strand break, that might be induced by Crispr, but the clear implication is it might be induced by anything.&rdquo;</p> <p>A third paper published concurrently with the Crispr results discussed the relationship between DNA damage and p53 in the context of RNAi activity.</p> <p>The Crispr studies showed successful editing of the sensitive cell may naturally inspire cell death, and, if instructed not to die, the edited cell may do so by inactivating its p53 pathway, which predisposes it ...</p><p><a href=https://www.benzinga.com/general/biotech/18/06/11888006/intellia-confirms-crispr-risk-irrelevant-to-its-program-with-no-adjus alt=Intellia Confirms Crispr Risk Irrelevant To Its Program, With No Adjustments Needed>Full story available on Benzinga.com</a></p> Biotech CRSP NTLA Thomas Barnes Health Care Top Stories Exclusives Interview General NTLA CRSP Biotech Health Care Top Stories Exclusives Interview General Benzinga Fri, 15 Jun 2018 18:22:30 +0000 Elizabeth Balboa 11888006 at https://www.benzinga.com Global Blood Therapeutics Shares Plunge After Sickle Cell Candidate Shows Reduced Effect https://www.benzinga.com/general/biotech/18/06/11887388/global-blood-therapeutics-shares-plunge-after-sickle-cell-candidate-s <p><strong>Global Blood Therapeutics Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gbt#NASDAQ">GBT</a>) shares were sliding&nbsp;Friday after the&nbsp;<a href="http://ir.globalbloodtx.com/phoenix.zhtml?c=254105&amp;p=irol-newsArticle&amp;cat=news&amp;id=2354718">release </a> of updated data for the company&#39;s&nbsp;sickle cell disease candidate that will be presented at the European Hematology Association Congress.</p> <h3><strong>What Happened</strong></h3> <p>Global Blood announced&nbsp;24-week data from its ongoing HOPE-KIDS 1 Study, an open-label Phase 2a study&nbsp;that evaluated its voxelotor in treating adolescents aged 6-17 years with SCD.</p> <p>Part B of the study evaluated 22 patients who received voxelotor 900mg/day and showed that 43 percent&nbsp;achieved hemoglobin response of greater than 1g/dL at 24 weeks, with a median hemoglobin change ...</p><p><a href=https://www.benzinga.com/general/biotech/18/06/11887388/global-blood-therapeutics-shares-plunge-after-sickle-cell-candidate-s alt=Global Blood Therapeutics Shares Plunge After Sickle Cell Candidate Shows Reduced Effect>Full story available on Benzinga.com</a></p> Biotech European Hematology Association Congress GBT News Trading Ideas GBT News Biotech Trading Ideas Benzinga Fri, 15 Jun 2018 15:33:11 +0000 Shanthi Rexaline 11887388 at https://www.benzinga.com Affimed Shares Slide On Updated Hodgkin Lymphoma Drug Combo Data https://www.benzinga.com/general/biotech/18/06/11886928/affimed-shares-slide-on-updated-hodgkin-lymphoma-drug-combo-data <p><strong>Affimed NV </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/afmd#NASDAQ">AFMD</a>) <a href="https://www.benzinga.com/news/18/06/11885186/40-biggest-movers-from-yesterday"> shares </a> were tumbling Friday&nbsp;after the <a href=" https://globenewswire.com/news-release/2018/06/15/1525071/0/en/Affimed-Announces-Updated-Data-of-AFM13-in-Combination-with-Keytruda-Pembrolizumab-in-Patients-with-Relapsed-Refractory-Hodgkin-Lymphoma-Presented-at-EHA.html"> release </a> of updated data on its Hodgkin lymphoma treatment candidate.</p> <p>The metric investors are reacting to may be&nbsp;a decline in complete metabolic response seen in the&nbsp;preliminary results.</p> <h3><strong>What Happened</strong></h3> <p>Affimed made a poster presentation at the European Hematology Association Congress of new interim data from a&nbsp;Phase 1b dose escalation study that evaluated AFM13, its lead NK cell engager candidate, in combination with <strong> Merck &amp; ...</strong></p><p><a href=https://www.benzinga.com/general/biotech/18/06/11886928/affimed-shares-slide-on-updated-hodgkin-lymphoma-drug-combo-data alt=Affimed Shares Slide On Updated Hodgkin Lymphoma Drug Combo Data>Full story available on Benzinga.com</a></p> AFMD Biotech MRK News Trading Ideas MRK US58933Y1055 AFMD News Biotech Trading Ideas Benzinga Fri, 15 Jun 2018 14:56:13 +0000 Shanthi Rexaline 11886928 at https://www.benzinga.com Charles River Laboratories Is A Leader In Biopharma Outsourcing, KeyBanc Says In Upgrade https://www.benzinga.com/analyst-ratings/analyst-color/18/06/11885982/charles-river-laboratories-is-a-leader-in-biopharma-out <p><strong>Charles River Laboratories Intl. Inc</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/crl#NYSE">CRL</a>), a preclinical and clinical laboratory service provider to the <a href="http://www.benzinga.com/topic/pharmaceutical">pharmaceutical</a>, medical device and biotechnology industries, is &quot;by far&quot; an industry leader, according to KeyBanc Capital Markets.&nbsp;</p> <h3><strong>The Analyst</strong></h3> <p>Analyst&nbsp;Donald Hooker upgraded <a href="https://www.benzinga.com/stock/crl">Charles River Laboratories</a>&nbsp;from Sector Weight to Overweight with a new $130 price target.</p> <h3><strong>The Thesis</strong></h3> <p>Charles River boasts the &quot;most comprehensive&quot; set of preclinical research products and services, which makes it a strategic outsourcing partner that its peers can&#39;t match, Hooker said in the upgrade note.</p> <p>The company&#39;s strategic positioning should help it sustain 6 percent or more revenue growth over the ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/18/06/11885982/charles-river-laboratories-is-a-leader-in-biopharma-out alt=Charles River Laboratories Is A Leader In Biopharma Outsourcing, KeyBanc Says In Upgrade>Full story available on Benzinga.com</a></p> Analyst Color Biotech CRL Donald Hooker KeyBanc Capital Markets Upgrades Price Target Analyst Ratings General CRL US1598641074 Analyst Color Biotech Upgrades Price Target Analyst Ratings General Benzinga Fri, 15 Jun 2018 13:23:41 +0000 Jayson Derrick 11885982 at https://www.benzinga.com Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug https://www.benzinga.com/general/biotech/18/06/11885131/benzingas-daily-biotech-pulse-hematology-conference-in-the-spotlight- <p>Here&#39;s a roundup of top developments in the biotech space over the last 24 hours.</p> <h3>Scaling the Peaks</h3> <p><em>(Stocks hitting 52-week highs on June 14)</em></p> <ul> <li><strong>ABIOMED, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abmd#NASDAQ">ABMD</a>)</li> <li><strong>AngioDynamics, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ango#NASDAQ">ANGO</a>)</li> <li><strong>BioLife Solutions Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blfs#NASDAQ">BLFS</a>)</li> <li><strong>BIO-TECHNE Corp </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tech#NASDAQ">TECH</a>)</li> <li><strong>CONMED Corporation </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cnmd#NASDAQ">CNMD</a>)</li> <li><strong>Cytosorbents Corp </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctso#NASDAQ">CTSO</a>)</li> <li><strong>Emergent Biosolutions Inc </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ebs#NYSE">EBS</a>)</li> <li><strong>Endologix, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elgx#NASDAQ">ELGX</a>)</li> <li><strong>Galectin Therapeutics Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/galt#NASDAQ">GALT</a>)</li> <li><strong>Haemonetics Corporation </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hae#NYSE">HAE</a>)</li> <li><strong>ICU Medical, Incorporated </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icui#NASDAQ">ICUI</a>)</li> <li><strong>Integra Lifesciences Holdings Corp </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iart#NASDAQ">IART</a>)</li> <li><strong>Kindred Biosciences Inc </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kin#NASDAQ">KIN</a>)</li> <li><strong>Mirati Therapeutics Inc </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrtx#NASDAQ">MRTX</a>)</li> <li><strong>Neogen Corporation </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/neog#NASDAQ">NEOG</a>)</li> <li><strong>Qiagen NV </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/qgen#NYSE">QGEN</a>)</li> <li><strong>SurModics, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/srdx#NASDAQ">SRDX</a>)</li> <li><strong>Ultragenyx Pharmaceutical Inc </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rare#NASDAQ">RARE</a>)</li> </ul> <h3>Down In The Dumps</h3> <p><em>(Stocks hitting 52-week lows on June 14)</em></p> <ul> <li><strong>Achieve Life Sciences Inc </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/achv#NASDAQ">ACHV</a>)</li> <li><strong>Atossa Genetics Inc </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atos#NASDAQ">ATOS</a>)</li> <li><strong>Evelo Biosciences Inc </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evlo#NASDAQ">EVLO</a>)</li> <li><strong>Intec Pharma Ltd </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntec#NASDAQ">NTEC</a>)</li> <li><strong>MiMedx Group Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdxg#NASDAQ">MDXG</a>)</li> <li><strong>Sonoma Pharmaceuticals Inc </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snoa#NASDAQ">SNOA</a>)</li> <li><strong>TESARO Inc </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsro#NASDAQ">TSRO</a>)</li> </ul> <h3>Stocks In Focus</h3> <h3>Verastem Announces Common Stock Offering</h3> <p><strong>Verastem Inc </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vstm#NASDAQ">VSTM</a>) <a href="https://www.businesswire.com/news/home/20180614006177/en/Verastem-Oncology-Announces-43.0-Million-Offering-Common">announced</a> a registered sale of 7.17 million shares to funds managed by Consonance Capital, priced at $6 per share. The company expects to realize gross proceeds of ...</p><p><a href=https://www.benzinga.com/general/biotech/18/06/11885131/benzingas-daily-biotech-pulse-hematology-conference-in-the-spotlight- alt=Benzinga&#039;s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug>Full story available on Benzinga.com</a></p> ABMD ACHV AFMD ANGO ARQL ATOS BGNE Biotech BLFS BLRX BPMC CNMD CTSO EBS ELGX EPZM EVLO GALT GBT HAE IART ICUI INVVY KIN KPTI LJPC MDXG MOR MRK MRTX MYL NEOG News NTEC QGEN RARE RARX RDY SELB SNOA SRDX STML TECH TSRO VSTM Offerings FDA Top Stories Pre-Market Outlook Trading Ideas MOR ABMD US0036541003 ANGO US03475V1017 ARQL US04269E1073 CNMD US2074101013 ELGX US29266S1069 IART US4579852082 ICUI US44930G1076 LJPC US5034594060 MYL US6285301072 NEOG US6404911066 QGEN NL0000240000 SRDX US8688731004 TECH US8783771004 EBS US29089Q1058 HAE US4050241003 MRK US58933Y1055 RDY US2561352038 BLRX CTSO VSTM GALT TSRO MDXG ATOS STML EPZM MRTX KPTI KIN RARE BLFS AFMD INVVY BPMC GBT NTEC BGNE EVLO SELB RARX SNOA ACHV News Biotech Offerings FDA Top Stories Pre-Market Outlook Trading Ideas Benzinga Fri, 15 Jun 2018 13:13:10 +0000 Shanthi Rexaline 11885131 at https://www.benzinga.com Cryo-Cell Consummates Acquisition of CORD:USE Assets and Extends Its Leadership Position Into the Public Cord Blood Banking Arena https://www.benzinga.com/pressreleases/18/06/g11886464/cryo-cell-consummates-acquisition-of-cord-use-assets-and-extends-its-l <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p>OLDSMAR, Fla., June 15, 2018 (GLOBE NEWSWIRE) -- <strong>Cryo-Cell International, Inc. </strong>(OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/CCEL#OTCQB" rel="nofollow">CCEL</a>) (the "Company"), the world&#039;s first private cord blood bank to separate and store stem cells in 1992, announced that it has completed its acquisition of  substantially all of the assets of CORD:USE Cord Blood Bank, Inc. ("CORD:USE") for an upfront purchase price of $14,000,000 plus up to $200 million  in potential  cash earnouts related to the CORD:USE public cord blood inventory and additional stock earnouts based upon Cryo-Cell achieving certain milestones associated with the purchased assets.  The Company does not expect that the full earnout related to the public cord blood inventory will be earned.</p> <p align="justify">&#34;Cryo-Cell is very pleased to have been able to close this transaction efficiently due to the cooperative efforts of the CORD:USE team," commented  David Portnoy, Cryo-Cell International&#039;s Chairman and Co-CEO.  He continued, "We believe that the growing clinical use of cord blood together with our entry into the public cord blood banking field bodes well for our shareholders."</p> <p align="justify">&#34;As the CEO of CORD:USE, and as importantly, an obstetrician, I believe it is critical to provide expectant parents with the highest quality cord blood and cord tissue banking services available. Having completed this acquisition, I believe that Cryo-Cell will now be providing the highest quality services to families interested in either family or public cord blood banking,&#34; said Edward S. Guindi M.D., President and CEO ...</p><p><a href=https://www.benzinga.com/pressreleases/18/06/g11886464/cryo-cell-consummates-acquisition-of-cord-use-assets-and-extends-its-l alt=Cryo-Cell Consummates Acquisition of CORD:USE Assets and Extends Its Leadership Position Into the Public Cord Blood Banking Arena>Full story available on Benzinga.com</a></p> Biotech CCEL Health Care Press Releases General CCEL Biotech Health Care Press Releases General Benzinga Fri, 15 Jun 2018 13:00:00 +0000 Globe Newswire 11886464 at https://www.benzinga.com BMO: Aeglea Has A Potentially Market-Conquering Arginase Deficiency Candidate, Oncology Opportunity https://www.benzinga.com/analyst-ratings/analyst-color/18/06/11880458/bmo-aeglea-has-a-potentially-market-conquering-arginase <p><strong>Aeglea Bio Therapeutics Inc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agle#NASDAQ">AGLE</a>) hasn&rsquo;t received much attention in its two years on the market, but on Thursday it caught the eye of its fourth analyst and fourth bull.</p> <h3> <strong>The Rating</strong></h3> <p>BMO Capital Markets analyst Matthew Luchini initiated coverage of&nbsp;<a href="https://www.benzinga.com/stock/agle">Aeglea </a>with an Outperform rating and $21 price target.</p> <h3> <strong>The Thesis</strong></h3> <p>BMO expects Aeglea&rsquo;s pegzilarginase to transform the treatment of Arginase I Deficiency (ARG1-D), which currently lacks <a href="https://www.benzinga.com/general/biotech">effective therapies</a>.</p> <p>&ldquo;Pegzilarginase could be the standard of care in ARG1-D, a nearly $400-million unadjusted peak sales opportunity,&rdquo; Luchini said in a note. The analyst forecast that Aeglea will capture 90 percent of the market within ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/18/06/11880458/bmo-aeglea-has-a-potentially-market-conquering-arginase alt=BMO: Aeglea Has A Potentially Market-Conquering Arginase Deficiency Candidate, Oncology Opportunity>Full story available on Benzinga.com</a></p> AGLE Analyst Color Biotech BMO Capital Markets Matthew Luchini Price Target Initiation Analyst Ratings General AGLE Analyst Color Biotech Price Target Initiation Analyst Ratings General Benzinga Thu, 14 Jun 2018 14:50:09 +0000 Elizabeth Balboa 11880458 at https://www.benzinga.com Avinger Announces First Patients Enrolled in Post-Market Study Comparing Pantheris OCT Imaging to Intravascular Ultrasound https://www.benzinga.com/pressreleases/18/06/g11879331/avinger-announces-first-patients-enrolled-in-post-market-study-compari <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="left">REDWOOD CITY, Calif., June 14, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ" rel="nofollow">AVGR</a>), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the initiation of the SCAN study, a post-market study comparing optical coherence tomography (OCT) with intravascular ultrasound (IVUS) as a diagnostic imaging tool in the peripheral arteries. OCT is a light-based, high definition imaging modality, which generates no X-ray radiation. Avinger&#039;s proprietary Lumivascular technology utilizes OCT to provide real-time intravascular imaging during the treatment of peripheral artery disease. The Company&#039;s Pantheris image-guided atherectomy and Ocelot image-guided chronic total occlusion (CTO) crossing catheters are the only catheters available worldwide that incorporate the additional benefits of real-time intravascular imaging during PAD treatment.<br /></p> <p>While the FDA has already cleared OCT diagnostic claims for Avinger&#039;s Pantheris and Ocelot catheters, and reimbursement codes applicable to therapeutic peripheral interventions with the Company&#039;s Lumivascular catheters already exist, the results of the SCAN study are intended to support an initiative to gain incremental reimbursement for OCT diagnostic imaging in the peripheral arteries similar to the reimbursement currently provided for the use of IVUS in this setting. The study will enroll up to 20 subjects diagnosed with peripheral artery disease at two centers in the United States, with the goal to acquire at least 115 matched images generated by OCT and IVUS imaging for analysis. More specifically, OCT and IVUS images will be captured at identical positions within vessel segments so that a comparison can be made between the two imaging modalities. Dr. Edward Pavillard, a vascular surgeon at PA Vascular Institute, and Dr. Luke Sewall, an interventional radiologist and president of Vascular and Interventional Professionals, will serve as physician investigators in this ...</p><p><a href=https://www.benzinga.com/pressreleases/18/06/g11879331/avinger-announces-first-patients-enrolled-in-post-market-study-compari alt=Avinger Announces First Patients Enrolled in Post-Market Study Comparing Pantheris OCT Imaging to Intravascular Ultrasound>Full story available on Benzinga.com</a></p> AVGR Biotech Press Releases General AVGR Biotech Press Releases General Benzinga Thu, 14 Jun 2018 12:30:00 +0000 Globe Newswire 11879331 at https://www.benzinga.com Benzinga's Daily Biotech Pulse: FDA Nods For Teligent And Keytruda, Sonoma's Q4 Miss, Sage Inks Deal With Japan's Shionogi https://www.benzinga.com/general/biotech/18/06/11878190/benzingas-daily-biotech-pulse-fda-nods-for-teligent-and-keytruda-sono <p>Here&#39;s a roundup of top developments in the biotech space over the last 24 hours.</p> <h3> Scaling the Peaks</h3> <p><em>(Stocks hitting 52-week highs on June 13)</em></p> <ul> <li> <strong>ABIOMED, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abmd#NASDAQ">ABMD</a>)</li> <li> <strong>AngioDynamics, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ango#NASDAQ">ANGO</a>)</li> <li> <strong>Arrowhead Pharmaceuticals Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arwr#NASDAQ">ARWR</a>)</li> <li> <strong>BioLife Solutions Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blfs#NASDAQ">BLFS</a>)</li> <li> <strong>BIO-TECHNE Corp </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tech#NASDAQ">TECH</a>)</li> <li> <strong>CAS Medical Systems Inc </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/casm#NASDAQ">CASM</a>)</li> <li> <strong>Edwards Lifesciences Corp <strong> </strong></strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ew#NYSE">EW</a>)</li> <li> <strong><strong><strong>Galectin Therapeutics Inc. </strong> </strong></strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/galt#NASDAQ">GALT</a>)</li> <li> <strong><strong><strong>Helius Medical Technologies Inc</strong></strong></strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hsdt#NASDAQ">HSDT</a>)</li> <li> <strong><strong><strong>Insulet Corporation</strong></strong></strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/podd#NASDAQ">PODD</a>)</li> <li> <strong><strong><strong>Kindred Biosciences Inc</strong></strong></strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kin#NASDAQ">KIN</a>)</li> <li> <strong><strong><strong>MORPHOSYS AG/S ADR</strong></strong></strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mor#NASDAQ">MOR</a>)</li> <li> <strong><strong><strong>Neogen Corporation</strong></strong></strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/neog#NASDAQ">NEOG</a>)</li> <li> <strong><strong><strong>ResMed Inc.</strong></strong></strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rmd#NYSE">RMD</a>)</li> <li> <strong><strong><strong>Qiagen NV </strong> </strong></strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/qgen#NYSE">QGEN</a>)</li> <li> <strong><strong><strong>Viking Therapeutics Inc</strong></strong></strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vktx#NASDAQ">VKTX</a>)</li> <li> <strong><strong><strong>Xenon Pharmaceuticals Inc</strong></strong></strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xene#NASDAQ">XENE</a>)</li> </ul> <h3> <strong><strong>Down In The Dumps</strong></strong></h3> <p><em>(Stocks hitting 52-week lows on June 13)</em></p> <ul> <li> <strong><strong><strong>Achieve Life Sciences Inc</strong></strong></strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/achv#NASDAQ">ACHV</a>)</li> <li> <strong><strong><strong>Evelo Biosciences Inc</strong></strong></strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evlo#NASDAQ">EVLO</a>)</li> <li> <strong><strong><strong>Flex Pharma Inc</strong></strong></strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flks#NASDAQ">FLKS</a>)</li> <li> <strong><strong><strong>MiMedx Group Inc</strong></strong></strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdxg#NASDAQ">MDXG</a>)</li> <li> <strong><strong><strong>Scpharmaceuticals Inc</strong></strong></strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/scph#NASDAQ">SCPH</a>)</li> </ul> <h3> <strong><strong>Stocks In Focus</strong></strong></h3> <h3> <strong><strong>Teligent ...</strong></strong></h3><p><a href=https://www.benzinga.com/general/biotech/18/06/11878190/benzingas-daily-biotech-pulse-fda-nods-for-teligent-and-keytruda-sono alt=Benzinga&#039;s Daily Biotech Pulse: FDA Nods For Teligent And Keytruda, Sonoma&#039;s Q4 Miss, Sage Inks Deal With Japan&#039;s Shionogi>Full story available on Benzinga.com</a></p> ABMD ACHV ANGO ARWR Biotech BLFS CASM Earnings EVLO EW FLKS GALT GSK HSDT IBB KIN MDXG MOR MRK MYL NEOG News PODD QGEN RMD SAGE SCPH SNOA TECH TLGT VKTX XENE FDA Top Stories Pre-Market Outlook Trading Ideas MOR ABMD US0036541003 ANGO US03475V1017 ARWR US0427971009 CASM US1247692098 IBB US4642875565 MYL US6285301072 NEOG US6404911066 PODD US45784P1012 QGEN NL0000240000 TECH US8783771004 EW US28176E1082 GSK US37733W1053 MRK US58933Y1055 RMD US7611521078 GALT MDXG KIN BLFS SAGE VKTX XENE FLKS HSDT TLGT EVLO SNOA ACHV SCPH News Earnings Biotech FDA Top Stories Pre-Market Outlook Trading Ideas Benzinga Thu, 14 Jun 2018 12:11:59 +0000 Shanthi Rexaline 11878190 at https://www.benzinga.com Aptose Enters Into License Agreement With CrystalGenomics to Acquire CG-806 Rights in China https://www.benzinga.com/pressreleases/18/06/g11878636/aptose-enters-into-license-agreement-with-crystalgenomics-to-acquire-c <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="justify">SAN DIEGO and SEOUL, South Korea, June 14, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ" rel="nofollow">APTO</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/APS#TSX" rel="nofollow">APS</a>) today announced that they have entered into a license agreement with CrystalGenomics, Inc. (KOSDAQ:083790) for China rights to CG-806 (including People&#039;s Republic of China, Hong Kong and Macau). Aptose will now own worldwide rights (excluding Korea) to develop and commercialize CG-806, a first-in-class, highly potent oral small molecule being developed for acute myeloid leukemia (AML), B-cell malignancies and other hematologic malignancies.<br /></p> <table border="0"> <tr> <td> <table width="273" cellspacing="6" class="gnw_news_media_box" cellpadding="1" border="0"> <tr> <td class="gnw_media_bgcolor"> <table width="100%" align="center" border="0" cellspacing="0" cellpadding="0"> <tr> <td colspan="2"><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/c26a5833-f0f2-4a09-b1c3-daf3f772236c/en" rel="nofollow"><img src="https://resource.globenewswire.com/Resource/Download/c26a5833-f0f2-4a09-b1c3-daf3f772236c?size=2" border="0" width="268" height="100" alt="0_int_image001.jpg" /></a></td> </tr> </table> </td> </tr> </table> <p> <br /><br /> </p></td> </tr> </table> <p align="justify">Under the agreement, CrystalGenomics will receive an upfront payment of US $3 million and is eligible for development, regulatory and commercial-based milestones, as well as single-digit royalties on product sales in China. Total deal value for the China territory, including the upfront payment, is up to US $125 million.</p> <p align="justify">On May 7, 2018, Aptose exercised its option to  obtain the exclusive license from CrystalGenomics to develop and commercialize CG-806 worldwide outside of China and  Korea.  This new agreement extends that license agreement to include China.</p> <p align="justify">"Licensing rights to CG-806 to include the China territory was a strategic decision," said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose. "Our preclinical work with CG-806 has demonstrated its superior activity to other FLT3 inhibitors on AML patient samples, its superior ability to kill B-cell malignancy patient samples relative to ibrutinib, and a favorable safety profile.  We believe that CG-806 has the potential to serve as a transformational agent for multiple hematologic cancers, including AML, CLL and others."</p> <p align="justify">&#34;We are pleased to continue our relationship with the Aptose team, which recognized the exciting potential of CG-806 very early in its development," said Joong Myung Cho, Ph.D., Chairman and Chief Executive Officer of CrystalGenomics.  "They have been laser focused on IND-enabling studies of CG-806, and we look forward to seeing ...</p><p><a href=https://www.benzinga.com/pressreleases/18/06/g11878636/aptose-enters-into-license-agreement-with-crystalgenomics-to-acquire-c alt=Aptose Enters Into License Agreement With CrystalGenomics to Acquire CG-806 Rights in China>Full story available on Benzinga.com</a></p> APTO Biotech Licensing TSX:APS Press Releases General APTO TSX:APS Biotech Press Releases General Benzinga Thu, 14 Jun 2018 11:05:00 +0000 Globe Newswire 11878636 at https://www.benzinga.com ProQR to Present at the JMP Life Sciences Conference https://www.benzinga.com/pressreleases/18/06/g11878602/proqr-to-present-at-the-jmp-life-sciences-conference <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="left">LEIDEN, the Netherlands, June 14, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ" rel="nofollow">PRQR</a>), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the company will give a presentation at the JMP Life Sciences Conference. <br /></p> <p>On Thursday, June 21, 2018 at 11:30 am ET, Gerard Platenburg, Chief Innovation Officer of ProQR, will participate in an analyst led fireside chat during the JMP Life Sciences Conference. The conference is being held at The St. Regis New York, NY.</p> <p><strong>About ProQR</strong></p> <p>ProQR Therapeutics is dedicated to changing lives ...</p><p><a href=https://www.benzinga.com/pressreleases/18/06/g11878602/proqr-to-present-at-the-jmp-life-sciences-conference alt=ProQR to Present at the JMP Life Sciences Conference>Full story available on Benzinga.com</a></p> Biotech News PRQR Health Care Press Releases General PRQR News Biotech Health Care Press Releases General Benzinga Thu, 14 Jun 2018 11:00:00 +0000 Globe Newswire 11878602 at https://www.benzinga.com New England Journal of Medicine Publishes Novavax' NanoFlu Clinical Trial Data https://www.benzinga.com/pressreleases/18/06/g11876816/new-england-journal-of-medicine-publishes-novavax-nanoflu-clinical-tri <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <ul type="disc"> <li><em>NanoFlu<sup>TM</sup> Phase 1/2 trial data published in a peer-reviewed letter to the editor in </em>The New England Journal of Medicine</li> <li><em>NanoFlu demonstrates significantly improved immune responses against a panel of homologous and drifted A(H3N2) influenza viruses compared to leading licensed egg-based, high-dose flu vaccine in older adults</em></li> <li><em>Phase 2 trial of quadrivalent NanoFlu expected to begin in third quarter of 2018</em></li> </ul> <p align="justify">GAITHERSBURG, Md., June 13, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ" rel="nofollow">NVAX</a>) today announced that <em>The New England Journal of Medicine</em> (NEJM) published a peer-reviewed letter to the editor detailing the positive results from Novavax&#039; Phase 1/2 clinical trial in older adults comparing its Matrix- M™ adjuvanted nanoparticle seasonal influenza vaccine candidate (NanoFlu) to the leading licensed egg-based, high-dose influenza vaccine (IIV3-HD). The letter is available online at <a href="https://www.globenewswire.com/Tracker?data=WvLGx8h49VsX7_NjRhogmktCYmNVPamePAdwe3bhWTm5vcc_eX7hFimoQAGwqR7BBa6X6nrXXhsmb1DRbTFFGNDaWqr6JtUs6nuuAidJk16zsdFTINT42WSkVe-fji5o3Q3TcpHZSly3gqmQ_qTYKV7N5aUTRn6MAFdT1EUohN4=" rel="nofollow" target="_blank" rel="nofollow">www.nejm.org/doi/full/10.1056/NEJMc1803554</a>.</p> <p align="justify">"We are pleased to be able to share the detailed data from the NanoFlu Phase 1/2 clinical trial with the broader scientific community," said Stanley C. Erck, President and Chief Executive Officer of Novavax, Inc. "The low effectiveness of seasonal influenza vaccines, and in particular the A(H3N2) component of the vaccine, during the 2017-2018 season emphasizes the need for a more effective vaccine. Our non-egg-based, recombinant nanoparticle vaccine, when coupled with Matrix-M, potentially offers broader protection against rapidly evolving drift strain variants. We believe this addresses important public health challenges caused by influenza and offers a significant advantage over current influenza vaccines."</p> <p align="justify">In February 2018, Novavax ...</p><p><a href=https://www.benzinga.com/pressreleases/18/06/g11876816/new-england-journal-of-medicine-publishes-novavax-nanoflu-clinical-tri alt=New England Journal of Medicine Publishes Novavax&#039; NanoFlu Clinical Trial Data>Full story available on Benzinga.com</a></p> Biotech NVAX Health Care Press Releases General NVAX US6700021040 Biotech Health Care Press Releases General Benzinga Wed, 13 Jun 2018 21:05:04 +0000 Globe Newswire 11876816 at https://www.benzinga.com Flex Pharma Shares Plunge After Biotech Ends 2 Clinical Trials, Announces 60% Workforce Cut https://www.benzinga.com/general/biotech/18/06/11873924/flex-pharma-shares-plunge-after-biotech-ends-2-clinical-trials-announ <p><strong>Flex Pharma Inc </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flks#NASDAQ">FLKS</a>) shares are slumping on above-average volume Wednesday following a <a href="https://flexpharmainc.gcs-web.com/news-releases/news-release-details/flex-pharma-announces-corporate-update"> release </a> from the company announcing the scrapping of two clinical trials and the exploration of strategic options.</p> <p>The <a href="https://www.benzinga.com/news/18/06/11873564/mid-morning-market-update-markets-edge-higher-kornferry-beats-q4-views"> stock </a> was plummeting 67.5 percent at the time of publication.&nbsp;</p> <h3> <strong>What Happened</strong></h3> <p><a href="https://www.benzinga.com/stock/flks">Flex Pharma </a>is ending the ongoing Phase 2 clinical trials of its lead product candidate FLX-787, which was being investigated for both amyotrophic lateral sclerosis, or ALS, and Charcot-Marie-Tooth disorder, or CMT.&nbsp;</p> <p>The ...</p><p><a href=https://www.benzinga.com/general/biotech/18/06/11873924/flex-pharma-shares-plunge-after-biotech-ends-2-clinical-trials-announ alt=Flex Pharma Shares Plunge After Biotech Ends 2 Clinical Trials, Announces 60% Workforce Cut>Full story available on Benzinga.com</a></p> Biotech FLKS News Movers Trading Ideas FLKS News Biotech Movers Trading Ideas Benzinga Wed, 13 Jun 2018 15:15:35 +0000 Shanthi Rexaline 11873924 at https://www.benzinga.com